<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tuberculosis disease in children: Treatment and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tuberculosis disease in children: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tuberculosis disease in children: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lisa V Adams, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey R Starke, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3525107828"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Issues related to treatment and prevention of tuberculosis (TB) disease (active TB) in children will be reviewed here [<a href="#rid1">1-4</a>].</p><p>Issues related to epidemiology, clinical manifestations, and diagnosis of TB disease in children are discussed separately. (See  <a class="medical medical_review" href="/d/html/8007.html" rel="external">"Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>Issues related to diagnosis and treatment of TB infection (latent TB) in children are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8020.html" rel="external">"Tuberculosis infection (latent tuberculosis) in children"</a>.)</p><p class="headingAnchor" id="H149497320"><span class="h1">TERMINOLOGY AND DEFINITIONS</span><span class="headingEndMark"> — </span>TB terminology is inconsistent in the literature [<a href="#rid5">5</a>]. Relevant terms are defined in the table (<a class="graphic graphic_table graphicRef132526" href="/d/graphic/132526.html" rel="external">table 1</a>). Definitions for drug-resistant TB are summarized in the table (<a class="graphic graphic_table graphicRef138279" href="/d/graphic/138279.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H2161339526"><span class="h1">GENERAL TREATMENT PRINCIPLES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical diagnosis</strong> – TB in children is often diagnosed clinically, without bacteriologic confirmation (particularly among children under five years of age), given the difficulty of establishing a definitive diagnosis. (See  <a class="medical medical_review" href="/d/html/8007.html" rel="external">"Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis", section on 'Overview'</a>.)</p><p></p><p class="bulletIndent1">A clinical diagnosis of TB is strengthened in the setting of clinical and radiographic response to empiric treatment in a child with a positive test for TB infection (<a class="drug drug_general" data-topicid="10029" href="/d/drug information/10029.html" rel="external">tuberculin skin test</a> [TST] or interferon-gamma release assay [IGRA]). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug susceptibility testing</strong> – Culture-based drug-susceptibility testing should be performed on initial isolates from each site of disease. In the setting of negative cultures, the drug susceptibility test results for isolates from a presumed source person (if known or available) should be used to guide treatment decisions. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitrosamine impurities</strong> – In August 2020, the US Food and Drug Administration (FDA) announced detection of nitrosamine impurities in samples of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a> [<a href="#rid6">6</a>]. Some such compounds have been implicated as possible carcinogens in long-term animal studies, with toxicity largely related to cumulative exposure. </p><p></p><p class="bulletIndent1">We favor continued use of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for treatment of TB in children if acceptable to the patient and family, as the risk of not taking rifampin likely outweighs any potential risk from nitrosamine impurities. This approach is concordant with US FDA and United States Centers for Disease Control and Prevention (CDC) recommendations.  </p><p></p><p class="headingAnchor" id="H2925127711"><span class="h1">PULMONARY TB</span><span class="headingEndMark"> — </span>Inpatients with pulmonary TB should be placed on airborne infection isolation. (See  <a class="medical medical_review" href="/d/html/8000.html" rel="external">"Tuberculosis transmission and control in health care settings"</a>.)</p><p class="headingAnchor" id="H3167500381"><span class="h2">Empiric treatment</span><span class="headingEndMark"> — </span>Design of a treatment regimen strongly depends on understanding drug susceptibility of the child's or source person's isolate; efforts should be directed at obtaining this information as quickly as possible.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presumed drug-susceptible TB</strong> – Empiric treatment for presumed drug-susceptible TB should include standard four-drug therapy (<a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a>, and <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a>). (See <a class="local">'Traditional regimen (≥6 months)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Considerations for suspected drug-resistant TB</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for empiric treatment </strong>– The decision to treat empirically for drug-resistant TB (ie, a regimen including second-line drugs – pending conventional, culture-based drug susceptibility data) depends on the severity of clinical illness (smear positivity, presence of cavitary disease, certain forms of extrapulmonary disease) and the degree of suspicion for drug-resistant TB (given epidemiologic factors) (<a class="graphic graphic_table graphicRef108729" href="/d/graphic/108729.html" rel="external">table 3</a>). Demonstration of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> resistance on the Xpert MTB/RIF test should prompt initiation of treatment for drug-resistant TB while awaiting results of conventional, culture-based drug susceptibility testing.</p><p></p><p class="bulletIndent2">Children for whom an empiric treatment regimen for drug-resistant disease may be warranted include [<a href="#rid7">7</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with treatment failure (acid-fast bacilli sputum culture positive after four months of therapy, assuming drug sensitivity testing is not available, or poor response to traditional therapy)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with relapse (recurrent TB after apparent cure)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with exposure to an individual with infectious drug-resistant pulmonary TB</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with residence in or travel to a region with high prevalence of drug-resistant TB (see  <a class="medical medical_review" href="/d/html/8027.html" rel="external">"Epidemiology and molecular mechanisms of drug-resistant tuberculosis", section on 'Epidemiology'</a>)</p><p></p><p class="bulletIndent2">The approach to regimen selection is discussed below. (See <a class="local">'Drug-resistant TB'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical approach</strong> – Options for empiric treatment for drug-resistant disease include an expanded regimen (six or more drugs) or an abbreviated bedaquiline-containing regimen. Some clinicians may choose to start with an expanded regimen, with de-escalation once susceptibility data are available (either from a specimen obtained from the child or from the presumed source person). (See <a class="local">'Drug-resistant TB'</a> below.)</p><p></p><p class="headingAnchor" id="H1602287786"><span class="h2">Drug-susceptible TB</span></p><p class="headingAnchor" id="H979878081"><span class="h3">Regimen selection</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – The approach to regimen selection should be guided by patient age and clinical factors (<a class="graphic graphic_algorithm graphicRef138853" href="/d/graphic/138853.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age &lt;3 months</strong> − For children age &lt;3 months, we treat with the traditional six-month regimen (<a class="graphic graphic_table graphicRef50271" href="/d/graphic/50271.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef79897" href="/d/graphic/79897.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age 3 months to 11 years</strong> − For children age 3 months to 11 years with nonsevere, smear-negative, presumed drug-susceptible disease, we treat with the shortened (four-month) regimen (<a class="graphic graphic_table graphicRef50271" href="/d/graphic/50271.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef79897" href="/d/graphic/79897.html" rel="external">table 5</a>). (See <a class="local">'Shortened (four-month) regimen for nonsevere, smear-negative disease'</a> below.)</p><p></p><p class="bulletIndent2">For children in this age group who do not meet criteria for the shortened regimen, we treat with the traditional six-month regimen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age 12 to 16 years</strong> − For children age 12 to 16 years with nonsevere, smear-negative, presumed drug-susceptible disease, we treat with the shortened (four-month) regimen. (See <a class="local">'Shortened (four-month) regimen for nonsevere, smear-negative disease'</a> below.)</p><p></p><p class="bulletIndent2">For children in this age group who do not meet criteria for the shortened regimen, options include the traditional regimen for six months or the rifapentine-moxifloxacin-based regimen for four months (<a class="graphic graphic_table graphicRef131747" href="/d/graphic/131747.html" rel="external">table 6</a>).</p><p></p><p class="bulletIndent2">While some TB clinicians favor the rifapentine-moxifloxacin-based regimen given the shorter duration, others favor the traditional six-month regimen pending further outcome data with the rifapentine-moxifloxacin-based regimen. Additional factors warranting consideration in selection of the rifapentine-moxifloxacin-based regimen (including screening for risk of QT prolongation as well as other contraindications and infrastructure requirements) are discussed separately. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Rifapentine-moxifloxacin-based four-month regimen'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age 17 to 18 years</strong> − For children age 17 to 18 years, options include the traditional six-month regimen or the four-month rifapentine-moxifloxacin-based regimen (<a class="graphic graphic_table graphicRef131747" href="/d/graphic/131747.html" rel="external">table 6</a>). </p><p></p><p class="bulletIndent2">While some clinicians favor the rifapentine-moxifloxacin-based regimen given the shorter duration, others favor the traditional regimen pending further outcome data with the rifapentine-moxifloxacin-based regimen. Additional factors warranting consideration in selection of the rifapentine-moxifloxacin-based regimen (including screening for risk of QT prolongation as well as other contraindications and infrastructure requirements) are discussed separately. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Rifapentine-moxifloxacin-based four-month regimen'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regimens</strong> – Regimens for treatment of TB disease in children include the traditional (≥6 months) regimen and two shortened regimens:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Traditional six-month regimen</strong> – The traditional six-month regimen consists of <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a>, and <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> for eight weeks, followed by isoniazid and rifampin for 16 weeks, for most forms of TB (excluding TB meningitis and osteoarticular TB) (<a class="graphic graphic_table graphicRef50271" href="/d/graphic/50271.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef79897" href="/d/graphic/79897.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Shortened four-month regimen (for nonsevere, smear-negative disease)</strong> – The shortened four-month regimen consists of <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a> (with or without <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a>, according to local guidelines) for eight weeks, followed by isoniazid and rifampin for eight weeks (<a class="graphic graphic_table graphicRef50271" href="/d/graphic/50271.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef79897" href="/d/graphic/79897.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rifapentine-moxifloxacin-based four-month regimen </strong>– The rifapentine-moxifloxacin-based four-month regimen consists of <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a>, <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a>, and <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> for eight weeks, followed by rifapentine, isoniazid, and moxifloxacin for nine weeks (<a class="graphic graphic_table graphicRef131747" href="/d/graphic/131747.html" rel="external">table 6</a>). This regimen is for drug-susceptible pulmonary TB, in the absence of extrapulmonary involvement.</p><p></p><p class="headingAnchor" id="H3094796976"><span class="h3">Available regimens</span></p><p class="headingAnchor" id="H2132047861"><span class="h4">Traditional regimen (≥6 months)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical approach</strong> – The empiric traditional regimen includes three or four drugs: <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, and <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a>, with or without <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a>. The regimen is outlined in the tables (<a class="graphic graphic_table graphicRef50271" href="/d/graphic/50271.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef79897" href="/d/graphic/79897.html" rel="external">table 5</a>) [<a href="#rid2">2,3</a>]. </p><p></p><p class="bulletIndent1">Phases include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initiation phase – This two-month phase includes three or four drugs with the goal of reducing the mycobacterial burden rapidly.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continuation phase – This four-month phase includes <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> to target elimination of persistent mycobacteria. </p><p></p><p class="bulletIndent1">Issues related to administration logistics, monitoring, and efficacy for this regimen are discussed separately. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Traditional regimen (≥6 months)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of </strong><strong>ethambutol</strong> – Use of <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> is warranted in the following circumstances:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unknown drug susceptibility data (for the patient or source case), in setting of risk for <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> resistance </p><p class="bulletIndent2"><span class="glyph">•</span>Presence of AFB smear-positive disease or extensive radiographic involvement </p><p class="bulletIndent2"><span class="glyph">•</span>Presence of extrapulmonary TB  </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> may be excluded if the child and/or source person is known to have pan-susceptible TB, in the absence of the above factors. </p><p></p><p class="headingAnchor" id="H3635189716"><span class="h4">Shortened (four-month) regimen for nonsevere, smear-negative disease</span><span class="headingEndMark"> — </span>The shortened (four-month) regimen is outlined in the tables (<a class="graphic graphic_table graphicRef50271" href="/d/graphic/50271.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef79897" href="/d/graphic/79897.html" rel="external">table 5</a>); it was endorsed by the World Health Organization (WHO) in 2022 for treatment of children between 3 months and 16 years of age with nonsevere, smear-negative, presumed drug-susceptible disease (defined as pulmonary TB confined to one lobe); exclusions include cavitary disease, miliary TB, complex pleural effusion, clinically significant airway obstruction, and peripheral lymph node involvement [<a href="#rid2">2</a>]. In settings where rapid molecular testing with Xpert MTB/RIF is available, a result of negative, very low, low, or trace positive may be used as a proxy for smear-negative disease. (See <a class="local">'Regimen selection'</a> above.)</p><p>The regimen was evaluated in the SHINE trial (Shorter Treatment for Minimal Tuberculosis in Children) which included 1204 children &lt;16 years (median age 3.5 years) with nonsevere, smear-negative, presumed drug-susceptible TB (including 127 patients with HIV infection) in South Africa, Uganda, Zambia, and India [<a href="#rid8">8,9</a>]. Children were randomly assigned to treatment with a four-month regimen (as summarized above) or a traditional six-month regimen (which included a continuation phase of 16 weeks rather than 8 weeks). </p><p>The four-month regimen was found to be noninferior to the six-month regimen; the primary outcome (defined as treatment failure [extension, change, or restart of treatment or TB recurrence], loss to follow-up during treatment, or death by 72 weeks) was observed among 3 percent of patients in each group (adjusted difference -0.4 percentage points, 95% CI -2.2 to 1.5). Adverse events were comparable between the groups (occurring in approximately 8 percent of participants in each group); adherence and retention rates were high (94 and 95 percent, respectively).</p><p class="headingAnchor" id="H566615324"><span class="h4">Rifapentine-moxifloxacin-based four-month regimen</span><span class="headingEndMark"> — </span>The rifapentine-moxifloxacin-based regimen is outlined in the table (<a class="graphic graphic_table graphicRef131747" href="/d/graphic/131747.html" rel="external">table 6</a>) [<a href="#rid2">2,10,11</a>]. It was endorsed by the WHO in June 2021, and the United States Centers for Disease Control and Prevention (CDC) issued guidance for use in February 2022 [<a href="#rid2">2,11</a>]. The regimen may be used for nonpregnant patients (age ≥12 years, body weight ≥40 kg) with drug-susceptible pulmonary TB, in the absence of extrapulmonary involvement. (See <a class="local">'Regimen selection'</a> above.)</p><p>Important considerations for use of this regimen include ensuring fluoroquinolone susceptibility testing and monitoring for toxicity. Issues related to administration logistics and monitoring for this regimen are discussed separately. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Rifapentine-moxifloxacin-based four-month regimen'</a>.)</p><p>The study evaluating the rifapentine-moxifloxacin four-month regimen included 63 adolescents ≥12 years of age; a four-month regimen consisting of <a class="drug drug_general" data-topicid="10079" href="/d/drug information/10079.html" rel="external">rifapentine</a>, <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a>, and <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> was found to be noninferior to a traditional six-month regimen consisting of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, isoniazid, pyrazinamide, and <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> [<a href="#rid10">10</a>]. The data from this trial are discussed further separately. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Rifapentine-moxifloxacin-based four-month regimen'</a>.)</p><p class="headingAnchor" id="H211008684"><span class="h2">Drug-resistant TB</span><span class="headingEndMark"> — </span>Circumstances in which an empiric treatment regimen for drug-resistant disease may be warranted are outlined above. The regimens below are appropriate for confirmed drug-resistant TB and for empiric treatment of suspected drug-resistant TB. (See <a class="local">'Empiric treatment'</a> above.)</p><p class="headingAnchor" id="H3678129623"><span class="h3">General principles</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Definitions for drug-resistant TB are summarized in the table (<a class="graphic graphic_table graphicRef138279" href="/d/graphic/138279.html" rel="external">table 2</a>). Risk factors for drug-resistant TB are summarized in the table (<a class="graphic graphic_table graphicRef108729" href="/d/graphic/108729.html" rel="external">table 3</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>All-oral treatment preferred</strong> – Whenever possible, it is desirable to design a regimen that avoids use of an injectable agent [<a href="#rid12">12</a>]. This is particularly true for very young children and those with mild TB disease (ie, those with good nutrition, mild forms of extrapulmonary disease, and the absence of cavitation on chest radiography and human immunodeficiency virus [HIV] infection) [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1">According to WHO guidance issued in 2021, <a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">bedaquiline</a> and/or delamanid may be used to treat children and adolescents of all ages with multidrug-resistant (MDR)/rifampin-resistant TB [<a href="#rid14">14</a>]. This guidance enables all-oral treatment regimens for children and adolescents of all ages.</p><p></p><p class="bulletIndent1">Data and clinical experience support the use of <a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">bedaquiline</a>, <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, and fluoroquinolones in children [<a href="#rid2">2,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of </strong><strong>bedaquiline</strong><strong> </strong>– Development of a pediatric <a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">bedaquiline</a> formulation is underway; in the meantime, the available tablet formulation may be mixed with soft food or dissolved in water for pediatric administration [<a href="#rid16">16</a>]. Ideally bedaquiline should be given with food to maximize absorption [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1">Coadministration of <a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">bedaquiline</a> with <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a> or lopinavir/<a class="drug drug_general" data-topicid="9871" href="/d/drug information/9871.html" rel="external">ritonavir</a> should be avoided. Coadministration of bedaquiline with efavirenz is associated with reduced bedaquiline levels; coadministration of bedaquiline with lopinavir/ritonavir is associated with increased bedaquiline levels [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of delamanid</strong> – Guidance for use of delamanid in children ages 6 to 17 years was issued by the WHO in 2018 [<a href="#rid18">18</a>]. Dosing of delamanid in children between three and five years of age has become easier with the availability of a 25 mg dispersible formulation, indicated for children ≥10 kg [<a href="#rid2">2,19</a>]. WHO provides guidance for delamanid dosing for children between 3 to 10 kg; its expert panel concluded that the balance between desirable and undesirable effects probably favors its use [<a href="#rid2">2</a>]. In the United States use of delamanid is under Investigational New Drug (IND) status; it is approved in Europe, China, India, South Africa, and elsewhere. </p><p></p><p class="bulletIndent1">Delamanid should administered separately in time (ideally one hour) from other medications, including other antituberculous drugs and antiretroviral agents. Ideally delamanid should be given with food to maximize absorption [<a href="#rid2">2</a>].</p><p></p><p class="headingAnchor" id="H2182079492"><span class="h3">Approach to monoresistant or polyresistant TB</span><span class="headingEndMark"> — </span>The approach to treatment of monoresistant or polyresistant TB is outlined separately. (See  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Treatment of monoresistant TB'</a> and  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Treatment of polyresistant TB'</a>.)</p><p class="headingAnchor" id="H2254311047"><span class="h3">Approach to MDR-TB or XDR-TB</span><span class="headingEndMark"> — </span>For most children with uncomplicated pulmonary MDR-TB or extensively drug-resistant (XDR)-TB, we suggest treatment with an abbreviated regimen (6 to 12 months). Abbreviated regimens include an all-oral bedaquiline-containing regimen (duration 9 to 12 months) or an abbreviated bedaquiline-containing regimen (for children ≥14 years; duration 6 months); the approach depends on patient age and available resources including access to drugs and susceptibility testing (<a class="graphic graphic_algorithm graphicRef142109" href="/d/graphic/142109.html" rel="external">algorithm 2</a>) [<a href="#rid2">2</a>]. (See <a class="local">'Abbreviated regimens'</a> below.)</p><p>A longer, individualized regimen (all-oral regimen for at least 18 months) is warranted for patient groups without sufficient data for use of an abbreviated regimen and in settings with limited drug availability. Indications for a longer regimen include (see <a class="local">'Longer, individualized regimen'</a> below): </p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated, meningeal, or central nervous system disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Advanced HIV infection (CD4 &lt;50 cells/microL) and extrapulmonary disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensive (or advanced) TB disease, such as bilateral cavitary disease or extensive parenchymal damage on chest radiography</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contraindication to one or more drugs in the shorter-course regimens; these include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prior exposure to one or more agents in the regimen for more than one month (unless susceptibility to these drugs is confirmed)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Confirmed resistance or suspected ineffectiveness to a drug in the regimen (except <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> resistance)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intolerance to a drug in the regimen or risk of toxicity due to drug-drug interactions</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One or more drugs in the regimen are unavailable</p><p></p><p>Children with none of the above indications may be treated with an abbreviated regimen. </p><p>Pediatric dosing of second-line antituberculous drugs is summarized in the table (<a class="graphic graphic_table graphicRef88543" href="/d/graphic/88543.html" rel="external">table 7</a>). Use of second-line antituberculous agents in children is complicated by the lack of pediatric formulations for most of these drugs, which can lead to under- or over-dosing. </p><p class="headingAnchor" id="H2698953811"><span class="h4">Abbreviated regimens</span></p><p class="headingAnchor" id="H696275370"><span class="h5">Bedaquiline-based regimen (9 to 12 months)</span><span class="headingEndMark"> — </span>The 9- to 12-month bedaquiline-based regimen is described separately. (See  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Other bedaquiline-based regimens'</a>.)</p><p class="headingAnchor" id="H120353669"><span class="h5">Abbreviated bedaquiline-containing regimens</span><span class="headingEndMark"> — </span>Abbreviated <a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">bedaquiline</a> regimens include: </p><p class="bulletIndent1"><span class="glyph">●</span>BPaL: A six-month, all-oral regimen of <a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">bedaquiline</a>, <a class="drug drug_general" data-topicid="122334" href="/d/drug information/122334.html" rel="external">pretomanid</a>, and <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a> </p><p class="bulletIndent1"><span class="glyph">●</span>BPaLM: A six-month, all-oral regimen of BPaL plus <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a></p><p></p><p>These regimens may be used for children ≥14 years of age; further study is needed before they should be used for younger children. Evidence for use of these regimens is discussed separately. (See  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Abbreviated regimens'</a>.)</p><p class="headingAnchor" id="H368267602"><span class="h4">Longer, individualized regimen</span><span class="headingEndMark"> — </span>The approach to creating a longer, individualized regimen is described separately (<a class="graphic graphic_table graphicRef119120" href="/d/graphic/119120.html" rel="external">table 8</a>). (See  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Longer, individualized regimen'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of injectable agent</strong> – An all-oral regimen is preferred. If an injectable agent must be used, kanamycin and <a class="drug drug_general" data-topicid="9194" href="/d/drug information/9194.html" rel="external">capreomycin</a> (not available in the United States; limited availability elsewhere) are preferred; <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a> or <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> should be used in children only if (1) other options are not possible, (2) drug susceptibility testing confirms susceptibility, and (3) monitoring for both ototoxicity and nephrotoxicity can be performed [<a href="#rid13">13</a>]. Regular audiometry is critical for monitoring children receiving these drugs, given potential association between early hearing loss and diminished language acquisition [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Children on treatment for drug-resistant TB should be monitored at least monthly for adherence, response to treatment (eg, sputum analysis for those with pulmonary TB), and potential adverse events. Drug toxicity is common; in one meta-analysis of children treated for MDR-TB, it was reported in 39 percent of cases [<a href="#rid20">20</a>]. Similarly, in the series from Peru, adverse effects occurred in 42 percent of cases, although no events required suspension of therapy for &gt;5 days [<a href="#rid21">21</a>]. </p><p></p><p class="headingAnchor" id="H2783143064"><span class="h3">Role of surgery</span><span class="headingEndMark"> — </span>Issues related to surgery for treatment of drug-resistant TB are discussed further separately. (See  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Role of surgery'</a>.)</p><p class="headingAnchor" id="H513582364"><span class="h2">Administrative logistics and follow-up monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medication adherence</strong> – Individual case management with directly observed therapy is essential for all patients to ensure adherence and safety and to prevent emergence of drug resistance. This is discussed further separately. (See  <a class="medical medical_review" href="/d/html/8019.html" rel="external">"Adherence to tuberculosis treatment", section on 'Directly or video observed therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Education</strong> – Caregivers should be educated about the manifestations of drug toxicity. As an example, signs and symptoms of hepatic toxicity include anorexia, nausea, vomiting, dark urine, icterus, rash, pruritus, fatigue, fever, abdominal discomfort (particularly right upper quadrant discomfort), easy bruising or bleeding, and arthralgias. Other adverse events are summarized in the table (<a class="graphic graphic_table graphicRef88543" href="/d/graphic/88543.html" rel="external">table 7</a>). Adverse drug events should prompt medication discontinuation and clinical evaluation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up evaluation</strong> – Patients should be monitored at least monthly to assess for adherence, treatment response (improvement in symptoms, weight gain, and growth) and adverse drug events. Medications should be weight-adjusted monthly. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory monitoring</strong> – Drug-related hepatotoxicity is rare in children; routine laboratory monitoring is not warranted during treatment for drug-susceptible TB in the absence of underlying liver disease or development of symptoms suggestive of hepatotoxicity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sputum monitoring </strong>– For patients with negative initial acid-fast bacilli (AFB) smear and culture, sputum monitoring is not necessary. For patients with positive initial sputum AFB smear or culture, we obtain monthly sputum AFB smear and culture until two consecutive samples are culture negative. If positive sputum AFB smear and/or culture persists after two months of therapy, drug susceptibility testing should be repeated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiographic monitoring</strong> – During and following treatment, hilar adenopathy may persist for two to three years and should not be considered a poor response to therapy. Therefore, a normal radiograph is not necessary to discontinue treatment, and normal follow-up radiographs for discontinuation of treatment are not necessary in the absence of clinical deterioration [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">Repeat chest radiography is warranted for patients who are not improving on antituberculous treatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic drug monitoring</strong> – Routine therapeutic drug monitoring is not necessary; it may be useful in some circumstances such as malabsorption, risk for drug-drug interactions, renal insufficiency, diabetes mellitus, and poor response to first-line therapy with known or assumed susceptibility to first-line agents [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H3518552926"><span class="h2">Treatment failure</span><span class="headingEndMark"> — </span>Failure to respond to treatment based on bacteriologic, radiographic, and/or clinical findings (such as continued or worsening clinical symptoms, failure to gain weight or weight loss) should prompt careful review of the treatment regimen as well as assessment for adherence [<a href="#rid2">2</a>]. In addition, specimens for mycobacterial culture and drug susceptibility testing should be obtained. </p><p>The management approach may include adjusting the drug regimen and/or extending the duration of treatment; these decisions should be made in consultation with expert guidance. </p><p class="headingAnchor" id="H2225394886"><span class="h1">EXTRAPULMONARY TB</span><span class="headingEndMark"> — </span>The approach to treatment of extrapulmonary TB (regimen and duration) should be guided by the clinical presentation. (See related topics.)</p><p>Regimens for extrapulmonary TB are often similar to treatment of pulmonary TB; an important exception is central nervous system (CNS) TB; this is discussed separately. (See  <a class="medical medical_review" href="/d/html/128001.html" rel="external">"Central nervous system tuberculosis: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H2273658462"><span class="h1">IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME</span><span class="headingEndMark"> — </span>The term "immune reconstitution inflammatory syndrome" (IRIS) refers to paradoxical worsening of a preexisting infectious process with administration of treatment. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with HIV infection</strong> – Patients with HIV are at risk for IRIS in the setting of initiation of antituberculous therapy and/or ART [<a href="#rid23">23,24</a>]. This is discussed further separately. (See  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome", section on 'Tuberculosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without HIV infection</strong> – Clinical deterioration consistent with IRIS has been observed among immunocompetent children receiving antituberculous therapy [<a href="#rid25">25,26</a>]. In one study including 115 immunocompetent children, 10 percent developed paradoxical worsening within 15 to 75 days (median 39 days) of starting TB treatment; affected children with paradoxical reactions tended to be younger (median age at diagnosis of 26 months versus 66 months) [<a href="#rid26">26</a>]. The most common manifestation was worsening of preexisting pulmonary lesions (75 percent of cases); in addition, 25 percent of those experiencing IRIS developed disease manifestations in new anatomic locations.</p><p></p><p class="headingAnchor" id="H1555124218"><span class="h1">PATIENTS WITH HIV INFECTION</span><span class="headingEndMark"> — </span>For patients with HIV infection and TB disease (in the absence of central nervous system [CNS] involvement) who are not yet receiving antiretroviral therapy (ART), ART may be initiated within two weeks of starting antituberculosis therapy [<a href="#rid1">1,3,27,28</a>]. </p><p>For patients with HIV infection and CNS TB, the timing of ART initiation is discussed separately. (See  <a class="medical medical_review" href="/d/html/128001.html" rel="external">"Central nervous system tuberculosis: Treatment and prognosis", section on 'Antiretroviral therapy'</a>.)</p><p>Patients with HIV are at risk for immune reconstitution inflammatory syndrome. (See <a class="local">'Immune reconstitution inflammatory syndrome'</a> above.)</p><p>Issues related to treatment of TB in patients with HIV infection are discussed further separately. (See  <a class="medical medical_review" href="/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a> and  <a class="medical medical_review" href="/d/html/8030.html" rel="external">"Treatment of pulmonary tuberculosis in adults with HIV infection: Follow-up after initiation of therapy"</a> and  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults"</a> and  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Patients with HIV infection'</a>.)</p><p class="headingAnchor" id="H2590493058"><span class="h1">OUTCOMES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-susceptible TB</strong> – Outcomes for children with drug-susceptible TB are generally favorable. In one study including more than 29,000 children in South Africa, &lt;1 percent died during treatment and 89.5 percent were cured or completed treatment; increased mortality was observed in children &lt;2 years of age and in children with HIV infection (adjusted hazard ratio 3.13 and 6.85, respectively) [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-resistant TB</strong> – Relatively high rates of treatment success have been achieved among children with MDR-TB [<a href="#rid30">30-32</a>]. In a systematic review and meta-analysis including 875 patients in 18 countries, the treatment success rate was 78 percent [<a href="#rid32">32</a>]. Among those with HIV infection, the treatment success rate was higher among those who received ART (82 versus 56 percent). </p><p></p><p class="bulletIndent1">Use of <a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">bedaquiline</a>, delamanid, or <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a> can improve outcomes in children with MDR-TB; in one study including 119 children (of whom 18 received one or more of these drugs), favorable outcome (successful treatment completion or documented microbial cure) was observed more frequently among those who received these agents than among those who received standard second-line drugs (94 versus 80 percent) [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H2764570848"><span class="h1">TOOLS FOR PREVENTION</span><span class="headingEndMark"> — </span>Tools for prevention of TB include:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacille Calmette-Guérin (BCG) immunization (based on regional policy). (See  <a class="medical medical_review" href="/d/html/8022.html" rel="external">"Prevention of tuberculosis: BCG immunization and nutritional supplementation", section on 'Groups to consider for BCG vaccination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identification and treatment of TB infection (latent TB) – This is especially critical for those at high risk for progressing from TB infection to TB disease. (See  <a class="medical medical_review" href="/d/html/8020.html" rel="external">"Tuberculosis infection (latent tuberculosis) in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interventions to reduce transmission – Inpatients with pulmonary TB should be placed on airborne infection isolation; this and other aspects of infection control are discussed further separately. (See  <a class="medical medical_review" href="/d/html/8000.html" rel="external">"Tuberculosis transmission and control in health care settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Contact investigation is an essential tool to identify recently infected individuals who, once properly diagnosed, would benefit from treatment (for TB infection or TB disease) to reduce transmission. (See  <a class="medical medical_review" href="/d/html/8007.html" rel="external">"Tuberculosis disease in children: Epidemiology, clinical manifestations, and diagnosis", section on 'Contact tracing'</a>.)</p><p></p><p class="headingAnchor" id="H695730114"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111822.html" rel="external">"Society guideline links: Diagnosis and treatment of tuberculosis"</a>.)</p><p class="headingAnchor" id="H1589195205"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric treatment</strong> – For presumed drug-susceptible TB, empiric treatment consists of standard four-drug therapy (<a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a>, and <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a>). The decision to treat empirically for drug-resistant TB (pending drug susceptibility data) depends on the severity of illness and the degree of clinical suspicion for drug-resistant TB (<a class="graphic graphic_table graphicRef108729" href="/d/graphic/108729.html" rel="external">table 3</a>); patient groups for whom an empiric treatment regimen for drug-resistant disease may be warranted are summarized above. (See <a class="local">'Empiric treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-susceptible TB</strong> – The approach to regimen selection should be guided by patient age and clinical factors (<a class="graphic graphic_algorithm graphicRef138853" href="/d/graphic/138853.html" rel="external">algorithm 1</a>) (see <a class="local">'Regimen selection'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children age 3 months to 16 years with nonsevere, smear-negative, presumed drug-susceptible disease, we suggest treatment with the shortened (four-month) regimen (<a class="graphic graphic_table graphicRef50271" href="/d/graphic/50271.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef79897" href="/d/graphic/79897.html" rel="external">table 5</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Shortened (four-month) regimen for nonsevere, smear-negative disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children age &lt;3 months, and for children age 3 months to 11 years who do not meet criteria for the shortened regimen, we suggest treatment with the traditional six-month regimen (<a class="graphic graphic_table graphicRef50271" href="/d/graphic/50271.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef79897" href="/d/graphic/79897.html" rel="external">table 5</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Traditional regimen (≥6 months)'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children age 12 to 16 years who do not meet criteria for the shortened regimen, and for children age 17 to 18 years, options include the traditional six-month regimen or the four-month rifapentine-moxifloxacin-based regimen (<a class="graphic graphic_table graphicRef131747" href="/d/graphic/131747.html" rel="external">table 6</a>). While some favor the rifapentine-moxifloxacin-based regimen given its shorter duration, others favor the traditional regimen pending further outcome data with the rifapentine-moxifloxacin-based regimen in adolescents. </p><p></p><p class="bulletIndent2">Additional factors warranting consideration in selection of the rifapentine-moxifloxacin-based regimen (including screening for risk of QT prolongation and other contraindications) are discussed separately. (See  <a class="medical medical_review" href="/d/html/8015.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection", section on 'Rifapentine-moxifloxacin-based four-month regimen'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-resistant TB </strong>– Definitions are summarized in the table (<a class="graphic graphic_table graphicRef138279" href="/d/graphic/138279.html" rel="external">table 2</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monoresistant TB or polyresistant TB – The clinical approach varies depending on the pattern of drug resistance. Treatment options are discussed separately. (See  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Treatment of monoresistant TB'</a> and  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Treatment of polyresistant TB'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multidrug-resistant (MDR)-TB or extensively drug-resistant (XDR)-TB – For most children with uncomplicated pulmonary MDR-TB or XDR-TB, we suggest treatment with an abbreviated regimen (6 to 12 months) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Abbreviated regimens include an all-oral bedaquiline-containing regimen (duration 9 to 12 months) or an abbreviated bedaquiline-containing regimen (for children ≥14 years; duration 6 months); the approach depends on patient age and available resources including access to drugs and susceptibility testing (<a class="graphic graphic_table graphicRef88543" href="/d/graphic/88543.html" rel="external">table 7</a> and <a class="graphic graphic_algorithm graphicRef142109" href="/d/graphic/142109.html" rel="external">algorithm 2</a>). All-oral regimens should be used whenever possible.</p><p></p><p class="bulletIndent2">A longer, individualized regimen (all-oral regimen for at least 18 months) is warranted for patient groups without sufficient data for use of an abbreviated regimen and in settings with limited drug availability. Indications for a longer regimen include (see <a class="local">'Approach to MDR-TB or XDR-TB'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Disseminated, meningeal, or central nervous system (CNS) disease</p><p class="bulletIndent3"><span class="glyph">-</span>Patients with advanced HIV infection (CD4&lt;50 cells/microL) and extrapulmonary disease </p><p class="bulletIndent3"><span class="glyph">-</span>Pregnancy </p><p class="bulletIndent3"><span class="glyph">-</span>Extensive (or advanced) TB disease, such as bilateral cavitary disease or extensive parenchymal damage on chest radiography </p><p class="bulletIndent3"><span class="glyph">-</span>Contraindication to one or more drugs in the shorter-course regimens</p><p></p><p class="bulletIndent2">The approach to creation of a longer, individualized regimen is discussed separately (<a class="graphic graphic_table graphicRef119120" href="/d/graphic/119120.html" rel="external">table 8</a>). (See  <a class="medical medical_review" href="/d/html/8028.html" rel="external">"Treatment of drug-resistant pulmonary tuberculosis in adults", section on 'Longer, individualized regimen'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization, Guidance for national tuberculosis programmes on the management of tuberculosis in children. https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf?sequence=1 (Accessed on November 19, 2019).</li><li class="breakAll">WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents.
Geneva: World Health Organization; 2022. https://www.who.int/publications/i/item/9789240046832 (Accessed on May 23, 2023).</li><li class="breakAll">American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</li><li><a class="nounderline abstract_t">Jaganath D, Beaudry J, Salazar-Austin N. Tuberculosis in Children. Infect Dis Clin North Am 2022; 36:49.</a></li><li><a class="nounderline abstract_t">Behr MA, Kaufmann E, Duffin J, et al. Latent Tuberculosis: Two Centuries of Confusion. Am J Respir Crit Care Med 2021; 204:142.</a></li><li class="breakAll">US Food and Drug Administration. FDA Updates and Press Announcements on Nitrosamines in Rifampin and Rifapentine. https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-mitigate-shortages-rifampin-and-rifapentine-after-manufacturers-find-nitrosamine (Accessed on October 06, 2020).</li><li><a class="nounderline abstract_t">Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012; 186:953.</a></li><li><a class="nounderline abstract_t">Turkova A, Wills GH, Wobudeya E, et al. Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. N Engl J Med 2022; 386:911.</a></li><li><a class="nounderline abstract_t">Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials 2018; 19:237.</a></li><li><a class="nounderline abstract_t">Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med 2021; 384:1705.</a></li><li><a class="nounderline abstract_t">Carr W, Kurbatova E, Starks A, et al. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:285.</a></li><li class="breakAll">Management of Multidrug-Resistant Tuberculosis in Children: A FIELD GUIDE. Fifth Edition http://sentinel-project.org/wp-content/uploads/2022/04/DRTB-Field-Guide-2021_v5.1.pdf (Accessed on January 23, 2023).</li><li class="breakAll">World Health Organization. Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) https://www.who.int/tb/publications/2018/WHO_RapidCommunicationMDRTB.pdf (Accessed on August 25, 2021).</li><li class="breakAll">World Health Organization. Rapid communication on updated guidance on the management of tuberculosis in children and adolescents. https://www.who.int/publications-detail-redirect/9789240033450 (Accessed on September 27, 2021).</li><li><a class="nounderline abstract_t">Moodliar R, Aksenova V, Frias MVG, et al. Bedaquiline for multidrug-resistant TB in paediatric patients. Int J Tuberc Lung Dis 2021; 25:716.</a></li><li><a class="nounderline abstract_t">Svensson EM, du Bois J, Kitshoff R, et al. Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. Br J Clin Pharmacol 2018.</a></li><li><a class="nounderline abstract_t">Huynh J, Marais BJ. Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs. Ther Adv Infect Dis 2019; 6:2049936119864737.</a></li><li class="breakAll">World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: Interim policy guidance. Available at: http://apps.who.int/iris/bitstream/handle/10665/250614/9789241549899-eng.pdf;jsessionid=044DF19E602AD56EC47E859FCBE93AEB?sequence=1 (Accessed on June 05, 2018).</li><li><a class="nounderline abstract_t">Tyeku N, Apolisi I, Daniels J, et al. Pediatric delamanid treatment for children with rifampicin-resistant TB. Int J Tuberc Lung Dis 2022; 26:986.</a></li><li><a class="nounderline abstract_t">Ettehad D, Schaaf HS, Seddon JA, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:449.</a></li><li><a class="nounderline abstract_t">Drobac PC, Mukherjee JS, Joseph JK, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006; 117:2022.</a></li><li><a class="nounderline abstract_t">Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74:839.</a></li><li><a class="nounderline abstract_t">Cotton MF, Rabie H, Nemes E, et al. A prospective study of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected children from high prevalence countries. PLoS One 2019; 14:e0211155.</a></li><li><a class="nounderline abstract_t">Link-Gelles R, Moultrie H, Sawry S, et al. Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review. Pediatr Infect Dis J 2014; 33:499.</a></li><li><a class="nounderline abstract_t">Thampi N, Stephens D, Rea E, Kitai I. Unexplained deterioration during antituberculous therapy in children and adolescents: clinical presentation and risk factors. Pediatr Infect Dis J 2012; 31:129.</a></li><li><a class="nounderline abstract_t">Olive C, Mouchet F, Toppet V, et al. Paradoxical reaction during tuberculosis treatment in immunocompetent children: clinical spectrum and risk factors. Pediatr Infect Dis J 2013; 32:446.</a></li><li class="breakAll">World Health Organization. The use of antiretroviral drugs for treating and preventing HIV infection. https://apps.who.int/iris/bitstream/handle/10665/85321/9789241505727_eng.pdf;jsessionid=9EC517B7285AC23E7C1CEB3EBA720C9E?sequence=1 (Accessed on November 19, 2019).</li><li><a class="nounderline abstract_t">Kay A, Mendez-Reyes J, Devezin T, et al. Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis. Clin Infect Dis 2023; 76:10.</a></li><li><a class="nounderline abstract_t">Osman M, Lee K, Du Preez K, et al. Excellent Treatment Outcomes in Children Treated for Tuberculosis Under Routine Operational Conditions in Cape Town, South Africa. Clin Infect Dis 2017; 65:1444.</a></li><li><a class="nounderline abstract_t">Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax 2014; 69:458.</a></li><li><a class="nounderline abstract_t">Chiang SS, Starke JR, Miller AC, et al. Baseline Predictors of Treatment Outcomes in Children With Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study. Clin Infect Dis 2016; 63:1063.</a></li><li><a class="nounderline abstract_t">Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med 2018; 15:e1002591.</a></li><li><a class="nounderline abstract_t">Madzgharashvili T, Salindri AD, Magee MJ, et al. Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs. J Pediatric Infect Dis Soc 2021; 10:457.</a></li></ol></div><div id="topicVersionRevision">Topic 135189 Version 1.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf?sequence=1" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization, Guidance for national tuberculosis programmes on the management of tuberculosis in children. https://apps.who.int/iris/bitstream/handle/10665/112360/9789241548748_eng.pdf?sequence=1 (Accessed on November 19, 2019).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/publications/i/item/9789240046832" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents.

Geneva: World Health Organization; 2022. https://www.who.int/publications/i/item/9789240046832 (Accessed on May 23, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35168714" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Tuberculosis in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Latent Tuberculosis: Two Centuries of Confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Latent Tuberculosis: Two Centuries of Confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22983960" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Caring for children with drug-resistant tuberculosis: practice-based recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35263517" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29673395" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33951360" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35202353" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34802493" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bedaquiline for multidrug-resistant TB in paediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29952141" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31367376" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31367376" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36163672" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pediatric delamanid treatment for children with rifampicin-resistant TB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22373593" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740844" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Community-based therapy for children with multidrug-resistant tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24846578" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Therapeutic drug monitoring in the treatment of tuberculosis: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31260455" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A prospective study of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected children from high prevalence countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24736441" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Tuberculosis Immune Reconstitution Inflammatory Syndrome in children initiating Antiretroviral Therapy for HIV infection: A systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22016079" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Unexplained deterioration during antituberculous therapy in children and adolescents: clinical presentation and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23271443" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Paradoxical reaction during tuberculosis treatment in immunocompetent children: clinical spectrum and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23271443" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Paradoxical reaction during tuberculosis treatment in immunocompetent children: clinical spectrum and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36097966" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29048512" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Excellent Treatment Outcomes in Children Treated for Tuberculosis Under Routine Operational Conditions in Cape Town, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064441" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27458026" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Baseline Predictors of Treatment Outcomes in Children With Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29995958" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33347564" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
